1
2
Geenen, Joost W., Belitser, Svetlana, Vreman, Rick A., van Bloois, Martijn, Klungel, Olaf H., Boersma, Cornelis, Hovels, Anke M.
Veröffentlicht in: Geenen , J W , Belitser , S , Vreman , R A , van Bloois , M , Klungel , O H , Boersma , C & Hovels , A M 2020 , ' A novel method for predicting the budget impact of innovative medicines : validation study for oncolytics ' , European Journal of Health Economics , vol. 21 , no. 6 , pp. 845-853 . https://doi.org/10.1007/s10198-020-01176-x;
2020
Veröffentlicht in: Geenen , J W , Belitser , S , Vreman , R A , van Bloois , M , Klungel , O H , Boersma , C & Hovels , A M 2020 , ' A novel method for predicting the budget impact of innovative medicines : validation study for oncolytics ' , European Journal of Health Economics , vol. 21 , no. 6 , pp. 845-853 . https://doi.org/10.1007/s10198-020-01176-x;
2020
3
4
Peeters, Niels W. L., Vreman, Rick A., Cirkel, Geert A., Kersten, Marie José, van Laarhoven, Hanneke W. M., Timmers, Lonneke
Veröffentlicht in: Peeters , N W L , Vreman , R A , Cirkel , G A , Kersten , M J , van Laarhoven , H W M & Timmers , L 2023 , ' Systemic anticancer treatment in the Netherlands : Few hospitals treat many patients, many hospitals treat few patients ' , Health Policy , vol. 135 , 104865 . https://doi.org/10.1016/j.healthpol.2023.104865;
2023
Veröffentlicht in: Peeters , N W L , Vreman , R A , Cirkel , G A , Kersten , M J , van Laarhoven , H W M & Timmers , L 2023 , ' Systemic anticancer treatment in the Netherlands : Few hospitals treat many patients, many hospitals treat few patients ' , Health Policy , vol. 135 , 104865 . https://doi.org/10.1016/j.healthpol.2023.104865;
2023
5
Broekhoff, Thomas F., Sweegers, Carly C.G., Krijkamp, Eline M., Mantel-Teeuwisse, Aukje K., Leufkens, Hubert G.M., Goettsch, Wim G., Vreman, Rick A.
Veröffentlicht in: Broekhoff , T F , Sweegers , C C G , Krijkamp , E M , Mantel-Teeuwisse , A K , Leufkens , H G M , Goettsch , W G & Vreman , R A 2021 , ' Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios ' , Value in Health , vol. 24 , no. 6 , pp. 759-769 . https://doi.org/10.1016/j.jval.2020.09.021;
2021
Veröffentlicht in: Broekhoff , T F , Sweegers , C C G , Krijkamp , E M , Mantel-Teeuwisse , A K , Leufkens , H G M , Goettsch , W G & Vreman , R A 2021 , ' Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios ' , Value in Health , vol. 24 , no. 6 , pp. 759-769 . https://doi.org/10.1016/j.jval.2020.09.021;
2021